What does the data on gliflozins say?
Steyer, Élisabeth
What does the data on gliflozins say? - 2023.
39
The recent availability in France of two sodium-glucose co-transporter type 2 (SGLT2i) inhibitors, empagliflozin and dapagliflozin, both for the treatment of type 2 diabetes and heart failure with reduced ejection fraction, is based on very encouraging results from initial trials. They have also been shown to have a protective effect against the progression of kidney failure. These trials are consistent with real-life observations in countries where they were marketed earlier, with a reduction in all-cause mortality in particular.
What does the data on gliflozins say? - 2023.
39
The recent availability in France of two sodium-glucose co-transporter type 2 (SGLT2i) inhibitors, empagliflozin and dapagliflozin, both for the treatment of type 2 diabetes and heart failure with reduced ejection fraction, is based on very encouraging results from initial trials. They have also been shown to have a protective effect against the progression of kidney failure. These trials are consistent with real-life observations in countries where they were marketed earlier, with a reduction in all-cause mortality in particular.
Réseaux sociaux